A randomized, open-label, two-period, parallel group, crossover study to evaluate the pharmacokinetics of venlafaxine extended-release and DVS [desvenlafaxine] SR in healthy subjects who are extensive or poor cytochrome P450 2D6 substrate metabolizers

Trial Profile

A randomized, open-label, two-period, parallel group, crossover study to evaluate the pharmacokinetics of venlafaxine extended-release and DVS [desvenlafaxine] SR in healthy subjects who are extensive or poor cytochrome P450 2D6 substrate metabolizers

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs Desvenlafaxine (Primary) ; Venlafaxine (Primary)
  • Indications Depression; Depressive disorders
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 07 Feb 2013 Actual end date Jun 2007 added as reported by ClinicalTrials.gov.
    • 18 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top